Treatment-associated atrial fibrillation: ibrutinib-specific or class-specific?
How to avoid tumor lysis syndrome when treating CLL patients with venetoclax
Information is key: why patients need to be empowered to learn about their disease
Safety profiles of idelalisib, duvelisib and TGR-1202 in treating CLL
The progress of CLL research: towards targeted therapy